EWM
ITCI icon

Endurance Wealth Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Endurance Wealth Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-325
Closed -$5K – 535
2017
Q4 		$5K Hold
325
– – ﹤0.01% 452
2017
Q3 		$5K Buy
+325
New +$4.77K ﹤0.01% 443

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
PointState Capital
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Endurance Wealth Management's ITCI Position: Q1 2018 in Review

Endurance Wealth Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2018, closing a stake of 325 shares — an estimated $5K sold.

Endurance Wealth Management first reported a position in ITCI in Q3 2017 and held it in 2 quarters. The position peaked at $5K in Q4 2017. 131 funds tracked by Wall St. Rank hold ITCI as of Q1 2018.

  • Endurance Wealth Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2018 after selling out during the quarter.
  • Endurance Wealth Management sold 325 Intra-Cellular Therapies Inc. shares in Q1 2018, an estimated $5K.
  • Endurance Wealth Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2017 and held it in 2 quarters.
  • Endurance Wealth Management's Intra-Cellular Therapies Inc. position peaked at $5K in Q4 2017.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2018.

Based on Endurance Wealth Management's 13F filing for Q1 2018, filed 19 Apr 2018.